Lantern Pharma Inc. (LTRN) Financial Ratios
7 years of historical data (2018–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.04
↓-54% vs avg
5yr avg: 2.24
30Y Low1.1·High6.1
ROE
↓
-66.9%
↑-62% vs avg
5yr avg: -41.3%
30Y Low-67%·High-22%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LTRN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Lantern Pharma Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $23M | $34M | $46M | $66M | $87M | $120M | — | — |
| Enterprise Value | $15M | $27M | $25M | $28M | $36M | $101M | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 1.04 | 1.62 | 1.13 | 1.17 | 1.22 | 6.08 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LTRN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
LTRN Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -66.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -66.9% | -66.9% | -32.9% | -22.3% | -27.1% | -57.2% | -655.0% | — |
| ROA | -60.0% | -60.0% | -31.1% | -21.5% | -26.2% | -54.2% | -258.0% | -383.8% |
| ROIC | -100.6% | -100.6% | -70.4% | -55.3% | -90.7% | -3063.2% | — | — |
| ROCE | -71.4% | -71.4% | -36.9% | -22.6% | -27.5% | -56.9% | -655.0% | — |
LTRN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $8M exceeds total debt of $243657, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.34 | -0.53 | -0.66 | -0.72 | -0.97 | -1.31 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -70.63 | — | — | — | — |
Net cash position: cash ($8M) exceeds total debt ($243657)
LTRN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Lantern Pharma Inc.'s current ratio of 5.83x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 20.99x to 5.83x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.83 | 5.83 | 16.18 | 20.99 | 31.26 | 36.64 | 2.52 | 0.68 |
| Quick Ratio | 5.83 | 5.83 | 16.18 | 20.99 | 31.26 | 36.64 | 2.52 | 0.68 |
| Cash Ratio | 5.54 | 5.54 | 15.42 | 19.72 | 30.40 | 34.81 | 2.52 | 0.68 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
LTRN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Lantern Pharma Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 1.1% | 3.8% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 1.1% | 3.8% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $11M | $11M | $11M | $11M | $6M | $6M | $6M |
Peer Comparison
Compare LTRN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LTRNYou | $23M | -0.0 | — | — | — | — | -66.9% | -100.6% | — |
 ONCO | $1M | -0.1 | — | — | 77.6% | -778.2% | -110.6% | -32.8% | — |
 CASI | $2M | -0.1 | — | — | 39.1% | -138.8% | -301.8% | -153.0% | — |
 ALDX | $104M | -1.8 | — | — | — | — | -58.5% | -369.4% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 RXRX | $1B | -2.3 | — | — | -62.0% | -867.9% | -59.5% | -95.8% | — |
 SDGR | $992M | -9.4 | — | 79.7 | 55.7% | -65.2% | -26.3% | -39.4% | — |
 ABSI | $894M | -6.8 | — | — | -319.4% | -4454.2% | -62.5% | -58.0% | — |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 ACLX | $7B | -28.3 | — | — | 70.0% | -1135.6% | -53.4% | -46.2% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See LTRN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LTRN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LTRN vs ONCO
Side-by-side business, growth, and profitability comparison vs Onconetix, Inc..
Start ComparisonLTRN — Frequently Asked Questions
Quick answers to the most common questions about buying LTRN stock.
What is Lantern Pharma Inc.'s P/E ratio?
Lantern Pharma Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
What is Lantern Pharma Inc.'s ROE?
Lantern Pharma Inc.'s return on equity (ROE) is -66.9%. The historical average is -41.3%.
Is LTRN stock overvalued?
Based on historical data, Lantern Pharma Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.